| Dr Joaquin De Rojas, MD | |
|
1360 E Venice Ave, Venice, FL 34285-9066 | |
| (941) 488-2020 | |
| (941) 484-2200 |
| Full Name | Dr Joaquin De Rojas |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 10 Years |
| Location | 1360 E Venice Ave, Venice, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619387370 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | D84985 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sarasota Memorial Hospital | Sarasota, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Center For Sight Pl | 1658340294 | 51 |
News Archive
Children of mothers experiencing depressive symptoms are more at risk, as adolescents, of experiencing suicidal thoughts and attempting suicide.
N30 Pharmaceuticals, Inc. announced today that it has begun oral dosing of N91115 in a Phase 1 clinical trial. N91115, a novel inhibitor of S-nitrosoglutathione reductase (GSNOR), is being developed for the treatment of cystic fibrosis (CF).
The COVID Moonshot, a non-profit, open-science consortium of scientists from around the world dedicated to the discovery of globally affordable and easily-manufactured antiviral drugs against COVID-19 and future viral pandemics has received key funding of £8 million from Wellcome, on behalf of the Covid-19 Therapeutics Accelerator.
For the first time, a genetic link specific to risk of childhood leukemia has been identified, according to a team of researchers from Memorial Sloan-Kettering Cancer Center, St. Jude Children's Research Hospital, University of Washington, and other institutions. The discovery was reported online today in the journal Nature Genetics.
› Verified 1 days ago
| Entity Name | Center For Sight Pl |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386718468 PECOS PAC ID: 1658340294 Enrollment ID: O20040929001217 |
News Archive
Children of mothers experiencing depressive symptoms are more at risk, as adolescents, of experiencing suicidal thoughts and attempting suicide.
N30 Pharmaceuticals, Inc. announced today that it has begun oral dosing of N91115 in a Phase 1 clinical trial. N91115, a novel inhibitor of S-nitrosoglutathione reductase (GSNOR), is being developed for the treatment of cystic fibrosis (CF).
The COVID Moonshot, a non-profit, open-science consortium of scientists from around the world dedicated to the discovery of globally affordable and easily-manufactured antiviral drugs against COVID-19 and future viral pandemics has received key funding of £8 million from Wellcome, on behalf of the Covid-19 Therapeutics Accelerator.
For the first time, a genetic link specific to risk of childhood leukemia has been identified, according to a team of researchers from Memorial Sloan-Kettering Cancer Center, St. Jude Children's Research Hospital, University of Washington, and other institutions. The discovery was reported online today in the journal Nature Genetics.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joaquin De Rojas, MD 1360 E Venice Ave, Venice, FL 34285-9066 Ph: (941) 488-2020 | Dr Joaquin De Rojas, MD 1360 E Venice Ave, Venice, FL 34285-9066 Ph: (941) 488-2020 |
News Archive
Children of mothers experiencing depressive symptoms are more at risk, as adolescents, of experiencing suicidal thoughts and attempting suicide.
N30 Pharmaceuticals, Inc. announced today that it has begun oral dosing of N91115 in a Phase 1 clinical trial. N91115, a novel inhibitor of S-nitrosoglutathione reductase (GSNOR), is being developed for the treatment of cystic fibrosis (CF).
The COVID Moonshot, a non-profit, open-science consortium of scientists from around the world dedicated to the discovery of globally affordable and easily-manufactured antiviral drugs against COVID-19 and future viral pandemics has received key funding of £8 million from Wellcome, on behalf of the Covid-19 Therapeutics Accelerator.
For the first time, a genetic link specific to risk of childhood leukemia has been identified, according to a team of researchers from Memorial Sloan-Kettering Cancer Center, St. Jude Children's Research Hospital, University of Washington, and other institutions. The discovery was reported online today in the journal Nature Genetics.
› Verified 1 days ago
P Dee G Stephenson, M.D., P.A. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 200 Palermo Pl, Venice, FL 34285 Phone: 941-485-1121 Fax: 941-486-0571 | |
Dr. Jesse Thomas Mccann, MD PHD Ophthalmology Medicare: Medicare Enrolled Practice Location: 1360 E Venice Ave, Venice, FL 34285 Phone: 941-488-2020 Fax: 941-484-2200 | |
Dr. Priya Mary Mathews, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1360 E Venice Ave, Venice, FL 34285 Phone: 941-488-2020 | |
Donald Alvin Mceachern, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1511 Tamiami Trl S, Suite 201, Venice, FL 34285 Phone: 941-497-2138 Fax: 941-493-2598 | |
John P Fezza, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1370 E Venice Ave Ste 205, Venice, FL 34285 Phone: 941-488-2020 | |
Dr. Mark Anthony Johnson, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 811 Ridgewood Avenue, Venice, FL 34285 Phone: 941-480-0600 Fax: 941-485-8090 | |
Dr. William John Mestrezat, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1360 E Venice Ave, Venice, FL 34285 Phone: 941-488-2020 Fax: 941-484-2200 |